GLP-1 drugs represent a step towards even more effective management of that risk." -Professor Robert Storey, Professor of Cardiology, University of Sheffield, commenting on the NICE guidance, April 2026 What the Trials Have Shown The pivotal trial underpinning the NICE decision is the SELECT study, a large-scale randomised controlled trial examining the cardiovascular outcomes of semaglutide in people with established heart and circulatory disease who are overweight
Priebe W, Krawczyk M, Kuo MT, Yamane Y, Savaraj N, Ishikawa T
When your ALT levels are high, it signals poor metabolic health
Zarse K, Schulz TJ, Birringer M, Ristow M: Impaired respiration is positively correlated with decreased life span in Caenorhabditis elegans models of Friedreich Ataxia
The vita glow infusion is one of the most requested treatments for those pursuing a more even skin tone and a radiant complexion
When considering study drug discontinuation or use of rescue medication (trial product estimand results), the weight loss resulting from the use of oral semaglutide was up to 5 kg, while that associated with other active comparators ranged from 0.8 to 3.8 kg, and that associated with placebo ranged from 0.1 to + 0.6 kg [35,36,37,38,39,40]